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Dementia with Lewy Bodies (DLB) was initially identified and confirmed primarily by pathology, but is soon to be
incorporated into the Diagnostic and Statistical Manual criteria as a clinical disease entity. Despite these advances
over more than 20 years, current data suggest that the sensitivity of accurate clinical diagnosis of DLB is still very
low, although there is mounting evidence that supportive features may increase diagnostic accuracy. Although DLB
remains easy to identify pathologically with different cellular pathologies differentiating it from other dementia
syndromes, pathological identification using only Lewy body pathology has been shown to be inaccurate due to
overlap with patients without dementia symptoms. A number of studies now suggest that a combination of
cellular pathologies, which include α-synuclein and β-amyloid deposition as well as dopamine denervation, assist
with differentiating this dementia syndrome from others. The clinical and pathological overlap with the tauopathy
of Alzheimer’s disease still remains to be clarified. To determine more robust and independent clinicopathological
correlates from Alzheimer’s disease, longitudinal prospective studies, using specific clinical batteries on dementia
patients reaching the proposed criteria for DLB, with post-mortem assessment of the multiple pathologies
associated with dementia, are required. Identifying genetic causes for DLB is another approach to investigate the
pathogenesis of DLB. However this approach has been hindered to date by difficulties with identifying DLB
clinically. The use of novel techniques is likely to advance knowledge on the pathogenesis of DLB and assist with
redefining clinical and pathologic diagnostic criteria. To achieve the goal of more accurate clinical diagnosis of DLB,
breakthroughs are necessary on the pathogenesis of DLB.
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The Lewy body was named after Frederick Lewy who first
described the abnormal intracytoplasm inclusions in 1912
in a patient with what is now called Parkinson’s disease
(PD). In 1961, Okazaki first described a relationship be-
tween the presence of cortical Lewy bodies and demen-
tia [1]. In 1984, Kosaka, Yoshimura, Ikeda and Budka
reviewed the existing literature and proposed that these
cases should be regarded as a new disease entity, which
they termed ‘diffuse Lewy body disease’ [2]. Soon after the
disease was confirmed by others [3,4]. The terminology of
dementia with Lewy bodies (DLB) was proposed by scien-
tists attending the 1996 proceedings of the First Inter-
national Workshop of the Consortium on DLB [5]. Before
1996 when the term DLB was designated, there were* Correspondence: g.halliday@neura.edu.au
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distribution, and reproduction in any mediumseveral terms to describe the appearance of Lewy bodies
in dementia, such as diffuse Lewy body disease, Lewy-
body dementia, senile dementia of the Lewy body type,
and dementia associated with cortical Lewy bodies [6]. As
DLB cases have been included in other dementia subtypes
(particularly Alzheimer’s disease or AD) in the past, its im-
portance can only be assessed if the diagnostic criteria
allow clear separation of the disorder from these other
types of dementia. DLB is now considered part of a
spectrum of Lewy body diseases, ie. PD, PD with dementia
(PDD) and DLB [7,8], and is known to often coexist with
AD (could be considered as a mixed dementia). To
emphasize its clinical features, Japanese scientists pro-
posed that DLB be called “Kosaka’s disease” [9], but this
term is yet to be internationally accepted. In fact, DLB
is not currently recognized as a diagnosis for dementia
in the Diagnostic and Statistical Manual (DSM) for Men-
tal Disorders published by the American PsychiatricCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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into the 5th version to be published in 2013.
The clinical criteria for possible and probable DLB diag-
nosis were last revised in 2005 following the 3rd DLB
International Workshop (Table 1) [8]. While the central
feature of progressive cognitive decline that interferes with
daily functioning is essential for diagnosis, the temporal
sequence for diagnosis allows this feature to occur with
progression in the context of a parkinsonian syndromeTable 1 Revised criteria for the clinical diagnosis of DLB
(2005)
1. Central feature (essential for a diagnosis of possible or probable
DLB)
Dementia defined as progressive cognitive decline of sufficient
magnitude to interfere with normal social or occupational function.
2. Core features (two core features are sufficient for a diagnosis of
probable DLB, and one for possible DLB)
Fluctuating cognition with pronounced variations in attention and
alertness
Recurrent visual hallucinations that are typically well formed and
detailed
Spontaneous features of parkinsonism
3. Suggestive features
REM sleep behaviour disorder
Severe neuroleptic sensitivity
Low dopamine transporter uptake in basal ganglia demonstrated by
SPECT or PET imaging.
4. Supportive features
Repeated falls and syncope
Transient, unexplained loss of consciousness
Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary
incontinence
Hallucinations in other modalities
Systematised delusions
Depression
Relative preservation of medial temporal lobe structures on CT/MRI
scan
Generalised low uptake on SPECT/PET perfusion scan with reduced
occipital activity
Abnormal (low uptake) MIBG myocardial scintigraphy
Prominent slow wave activity on EEG with temporal lobe transient
sharp waves
5. A diagnosis of DLB is less likely
In the presence of cerebrovascular disease evident as focal
neurologic signs or on brain imaging
In the presence of any other physical illness or brain disorder
sufficient to account in part or in total for the clinical picture
If parkinsonism only appears for the first time at a stage of severe
dementia
6. Temporal sequence of symptoms
DLB should be diagnosed when dementia occurs concurrently or
within one year of parkinsonism (if it is present).where it may only become prominent or persistent after
the first few years. An arbitrary ‘one-year rule’ introduced
at the same time as the disease entity in 1996 has been
continued to be recommended to be applied to distinguish
DLB from PDD: If dementia occurs within 12 months
of the motor features, the patient should be classified
as having a primary diagnosis of DLB [8], although the
‘one-year rule’ is not without challenge [7]. Additional
core features required for diagnosis include fluctuating
cognition with pronounced variations in attention and
alertness, recurrent visual hallucinations that are well
formed and detailed, and/or spontaneous features of par-
kinsonism. Possible DLB is identified if one of these fea-
tures is present, while probable DLB is identified if two of
these features are present. Three suggestive features were
included in 2005 to assist with a diagnosis of DLB; rapid
eye movement (REM) sleep behavior disorder, severe nar-
coleptic sensitivity and low dopamine transporter uptake
in basal ganglia demonstrated by SPECT or PET. If one or
more suggestive feature is present in addition to one core
feature, then probable DLB can be diagnosed. If one or
more suggestive feature is present in the absence of any
core feature, then possible DLB can be diagnosed. The
diagnosis of DLB is less likely 1) in the presence of cere-
brovascular disease evident as focal neurologic signs or on
brain imaging, 2) in the presence of any physical illness or
brain disorder sufficient to account in part or in total for
the clinical picture, and 3) if parkinsonism only appears
for the first time at a severe stage of dementia. This last
criterion appears to be the cause of much over-diagnosis
of DLB in current clinical practice (see below).
The accuracy of the diagnostic criteria for DLB is vari-
able depending on the populations assessed, with rela-
tively low clinical sensitivity (lowest 12%, although 88%
in recent work) but higher specificity (79-100%) [10-16].
There appears to be an increase in sensitivity with the
inclusion of new supportive features discussed above
[13,16]. In the six studies assessing the accuracy of clin-
ical diagnoses since the 2005 criteria, one report selected
cases where all clinical symptoms were assessed but
determined the accuracy of diagnosis only in those 53
cases with a clinical diagnosis of DLB [12]. A second
study of DLB patients assessed whether neuroimaging
was of assistance in 20 cases who came to autopsy, find-
ing that dopamine ligand imaging improved diagnosis
significantly (88% sensitivity, 100% specificity in this
small sample) [13]. A third study also assessed patients
with Lewy bodies only and determined which pathology
correlated most with the clinical phenotype, asserting
that the severity of neurofibrillary tangles relate more to
the diagnostic DLB criteria than Lewy bodies [10], con-
sistent with previous suggestions [11]. This was con-
firmed in a fourth study assessing 304 people 85 years
old and above [14]. A much larger series did not use the
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versus pathological diagnoses in 2,861 cases in the
National Alzheimer’s Coordinating Center registry [15].
The accuracy of diagnosing clinical AD was higher (85%
sensitivity, 51% specificity) than that for clinical DLB
(32% sensitivity for pure and 12% for mixed, 95% specifi-
city). However, the most recent study assessing 234 con-
secutive patients with dementia coming to autopsy has
shown that including REM sleep behavior disorder sig-
nificantly improves the diagnostic accuracy of clinical
DLB [16]. The still significant clinical under-detection of
probable DLB is discussed in this review. In addition, we
review the neuropathology of DLB and its overlapping
pathology with other disorders, as well as the genetics
and pathogenesis of DLB. We expect that as cellular and
molecular knowledge on DLB advances, the diagnostic
criteria for DLB will undergo further modifications.
Clinical presentation and differentiation of DLB
As stated above, significant cognitive decline is
mandatory for the diagnosis of DLB. Patients with DLB
usually have deficits on tests of attention, executive
function (e.g. planning, prioritizing, and sequencing) and
visuospatial ability. In a cross-sectional clinical study
[17], memory impairment (57%) was the most common
presenting symptom in DLB, followed by visual halluci-
nations (44%), depression (34%), problem solving diffi-
culties (33%), gait problems (28%), and tremor/stiffness
(25%). In contrast, 99% of AD carers reported impaired
memory as a presenting symptom, whereas visual hallu-
cinations were a presenting symptom in 3% of the AD
cases [17]. These observations support previous sugges-
tions that DLB should be suspected in mild memory im-
pairment cases with visual hallucinations [18], although
this feature is not highly prevalent in patients with aut-
opsy confirmed DLB [17]. In community studies [6,19],
DLB accounts for approximately 0.7% of the general
population older than 65 years of age, and 5% (3.3%
probable, 1.7% possible) of people over 85 years of age.
Hospital-based autopsy series report 10-15% of patients
with DLB and population-based autopsy series show
Lewy body pathology evenly distributed between demen-
ted and non-demented individuals, suggesting a substan-
tial pool of preclinical cases [6]. This has been confirmed
in more recent, expansive autopsy series [20]. The early
identification of DLB, as well as the differentiation of DLB
from other conditions, has become very important to
determine treatment options, help with behavioral man-
agement of patients, and provide informative resources
for caregivers.
Fluctuating cognition
Fluctuations may reflect periods of unresponsiveness
while awake (e.g., blanking out, zoning out), episodes ofexcessive somnolence despite adequate night-time sleep,
or periods of daytime behavioural confusion with limited
awareness of surroundings alternating with normal or
near normal function. Cognitive fluctuations have also
been described as variability in the patients’ cognitive or
functional abilities and periods when the patient regains
their ability to perform tasks that they were previously
unable to perform. However, studies show that fluctua-
tions in cognition are problematic to define and it is
hard to obtain consistent assessments for their presence
[11,21], which has been proposed as the main factor for
low sensitivity of the current clinical diagnosis criteria
[22]. To overcome this difficulty, there are several clinical
tests available for the evaluation of fluctuations: Clinician
Assessment of Fluctuation scale, semi-structured One Day
Fluctuation Assessment scale, and The Mayo Fluctuations
Composite Scale [11,23]. However, these tools have yet to
be evaluated for their reliability and validity [24]. As the
prevalence of this feature is high in autopsy confirmed
cases of DLB, clear and reliable assessment of fluctuating
cognition is warranted.
Recurrent visual hallucination
In DLB, visual hallucinations are typically recurrent and
well formed, consisting of three dimensional subjects,
people, children or animals. Visual misperceptions (illu-
sions) are also common [6,19,25]. Examples of object
misperceptions in DLB include mistaking a hinge for a
caterpillar, or patterns on a rug for snakes, etc. Auditory
hallucinations and delusional ideation can occur in a
subgroup of those with visual hallucinations [26]. The
most frequent delusional ideas include strangers or
intruders in the home or the belief that deceased friends
or family members are visiting, and examples of elemen-
tary auditory hallucinations include banging, knocking,
sizzling, a doorbell or footsteps. These are associated with
Lewy body counts in the anterior and inferior temporal
lobe, claustrum and the amygdala, regions previously
associated with complex visual image generation [27-30].
The presence of visual hallucinations and global cognitive
impairment are also associated with deficits in choline
acetyltransferase (ChAT) in DLB. ChAT is an indicator of
neocortical cholinergic activity, which is more depleted in
DLB than in AD [31]. It is unknown whether lower levels
of ChAT correlate with greater Lewy body loads in DLB.
The Neuropsychiatric Inventory (NPI) can be used in the
clinic to screen visual hallucinations and assess their se-
verity and frequency [32].
Spontaneous parkinsonism
The extrapyramidal signs should be spontaneous or occur
subsequent to dementia in DLB [7], although dementia is
allowed to occur within one year of earlier parkinsonism
according to the current temporal designation of DLB [8],
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facial immobility are axial features common in DLB, while
rest tremor of the limbs is less common. Levodopa re-
sponsiveness in DLB is also less common [33,34]. The
severity of motor features in DLB can be assessed using
the Unified Parkinson's Disease Rating Scale (UPDRS) [8].
Rapid eye movement (REM) sleep behavior disorder
REM sleep behavior disorder can develop in otherwise
neurologically-normal adults as well as in those with a
neurodegenerative disease [35]. REM sleep behavior dis-
order has been included as a supportive clinical feature
for DLB and has been shown to enhance the diagnosis
of DLB [16], possibly because it is a significant risk fac-
tor for both cognitive deficits and PD [36]. DLB patients
with probable REM sleep behavior disorder have an earl-
ier onset of other symptoms (parkinsonism and visual
hallucinations), a more rapid disease course and less AD
but similar Lewy-related pathologies compared with
DLB patients who do not have REM sleep behaviour dis-
order [37]. These observations suggest that REM sleep
behavior disorder in patients with DLB may indicate a
particular subtype of DLB.
Severe neuroleptic sensitivity
About 30 to 50% of DLB patients who take antipsychotic
drugs (olanzapine – 58%, clozapine – 11%, thioridazine –
6%) will develop severe neuroleptic sensitivity, manifested
as a sudden onset of drowsiness, increased confusion, im-
mobility, and muscle rigidity [38,39]. Severe neuroleptic
sensitivity is not seen in patients with AD, but occurs in
27% of patients with PD, 39% with PDD, and is most fre-
quent in patients with DLB (53%) [38]. It has been pro-
posed that this change in sensitivity is due to dysfunction
of dopamine D2 receptors [38]. As severe neuroleptic sen-
sitivity reactions can be fatal, more research and education
on this issue needs to be conducted [39].
Low dopamine transporter uptake in basal ganglia
demonstrated by SPECT or PET
Low dopamine transporter uptake in the basal ganglia,
measured with (123)I-FP-CIT (DaTSCAN) SPECT im-
aging or (18) fluorodopa PET, is clinically useful in dis-
tinguishing DLB from AD [40,41]. A retrospective study
showed that DaTSCAN findings were concordant with
the outcome clinical DLB diagnosis in 95% cases [42]. A
systematic meta-analysis of published studies on DLB
diagnostic accuracy of presynaptic dopaminergic im-
aging with DaTSCAN revealed 86.5% sensitivity and
93.6% specificity differentiating DLB from non-DLB [43].
Other imaging characteristics
Other supportive features include abnormal cardiac sympa-
thetic imaging using Iodine-123 Metaiodobenzilguanidine(I-123 MIBG), occipital and posterior parietotemporal lobe
hypometabolism [44], and relative preservation of medial
temporal lobe structures [45], etc. (Table 1).
Differentiation
AD and PDD are the two major disorders required to be
clinically differentiated from DLB. The most difficult syn-
drome to differentiate from DLB is AD, as prominent or
persistent memory impairment occurs in the early stages
of both disorders. In addition, DLB patients with con-
comitant AD are less likely to have hallucinations com-
pared to patients with pure DLB, possibly because the
clinical DLB features are masked by the clinical features of
AD [11]. A further difficulty has been that the characteris-
tic features of DLB can often manifest in AD patients
when the dementia has progressed to a severe stage, and
thus the majority of patients diagnosed with DLB have
had severe AD rather than DLB or mixed DLB and AD
pathologically [15]. These data show that the core clinical
features of DLB are only effective for clinical differenti-
ation from AD at the onset of disease [46]. This problem
with the overlap with pathologically proven AD may be
assisted with the inclusion of some of the supportive fea-
tures for DLB [16], but this needs to be evaluated further.
A recent study suggests that the assessment of non-motor
symptoms associated with PD (olfactory dysfunction, con-
stipation, increased saliva and signs of rapid eye move-
ment sleep behavior disorder) at the onset of dementia
can assist with differentiating DLB from AD [47]. Such
non-motor symptoms are being actively studied in large
clinical cohorts as prodromes for PD [48] with research
on potential prodromal features for DLB also currently
underway [49]. Such research may provide important yet-
to-be-defined differentiating features.
Differentiating PDD from DLB is currently an arbitrary
construct, but at least has proven less problematic. PDD
in the context of well-established PD when subsequent de-
mentia becomes evident is easily differentiable from the
dominant dementia syndrome observed in most cases of
DLB. The clinical diagnostic criteria for PDD have been
published and operationalised and use the three core fea-
tures of DLB [50,51]. While the clinical diagnostic criteria
for "probable" and "possible" PDD has been proposed with
a simple, pragmatic set of tests involved [50], the sensitiv-
ity (47%) of these tests for diagnosing dementia in the
context of PD is low [52]. While the differential diagnosis
between DLB and PDD is not problematic due to the arti-
ficial construct, the identification of all dementia cases in
patients with PD needs to be improved.
Pathological manifestations and differentiation of
DLB
The diagnosis of DLB is based on assessing the probabil-
ity that the pattern and degree of Lewy-related pathology
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order [19,53]. Currently, pure DLB is diagnosed patho-
logically according to the severity and distribution of
LRP in certain brain regions, and Braak neurofibrillary
stages less than stage IV [54,55]. Fibrillar forms of α-
synuclein are the major component of LRP (Figure 1)
[56]. At end stage, α-synuclein LRP is diffusely distribu-
ted in cortical and subcortical regions in both DLB and
PDD [6,57]. α-Synuclein-immunoreactive astrocytes are
also noted in PDD as well as in DLB (Figure 1) [58].
However, novel techniques including paraffin-embedded
tissue blotting and protein aggregate filtration assays re-
veal substantial accumulation of α-synuclein aggregates
in presynapses in DLB [59], suggesting that presynaptic
α-synuclein aggregates, rather LRP, cause neurodegen-
eration. Whether such techniques would assist with dif-
ferential diagnosis needs further examination.
At present there is a lot of controversy over the clin-
ical significance of LRP and so further refinement of
techniques in this area may be warranted. Patients with
pathologically-confirmed DLB are not all demented; 40-
80% of those have visual hallucinations, 50-80% develop
parkinsonism, and overall about 30-50% of subjects
demonstrate both visual hallucination and parkinsonism
in retrospective studies [11,50]. In one pathological sam-
ple, patients satisfying the McKeith criteria for diffuse
neocortical DLB with only mild concomitant AD path-
ology were demented only 48% of the time with only
54% displaying extrapyramidal symptoms [20]. However,
these clinical findings were gathered retrospectively
questioning whether the clinical assessment of these
patients was sufficiently detailed to discount the pres-
ence of other DLB features prior to autopsy. On the
other hand, widespread LRP occurs in many sporadic
AD cases without parkinsonian symptoms [60], some-
times reaching pathological criteria for both DLB and
AD [61]. In particular, familial DLB cases often show
concomitant DLB and AD [61]. Retrospective studies
show that DLB + AD patients have longer disease dura-
tions compared to patients with pure DLB pathology
[11]. Further population-based, longitudinal prospective
clinical and pathological correlation studies are war-
ranted to determine the clinical significance of LRP in
both the normal and dementia populations.
In comparison to LRP, β-amyloid plaques are often
seen in DLB compared to PDD [62-65]. Unlike AD, β-
amyloid plaques in pure DLB are diffuse and without tau
neuritic involvement [17]. Whether or not β-amyloid de-
position contributes to any DLB clinical feature particu-
larly, or more to the timing and/or severity of cognitive
decline, remains to be determined. The common occur-
rence of β-amyloid deposition in the setting of clinical
DLB may prove more difficult in terms of differentiation
from AD, although as discussed above, the assessment ofimaging for dopamine transporters seems to assist with
the differential diagnosis from AD [66]. This highlights
another important pathological aspect to assist with case
differentiation, the pattern of cell loss or atrophy. On
this aspect, not only can imaging dopamine cell loss as-
sist, but there is also more limited cortical and hippo-
campal atrophy in DLB versus AD [44]. There is even
more limited cell death in PDD, with hippocampal spar-
ing in comparison to DLB [28,67]. The overlap between
these disorders can best be seen as a pathological con-
tinuum with dopamine cell loss and widespread LRP
observed in both PDD and DLB, with additional β-
amyloid deposition and mild cortical and hippocampal
atrophy observed in pure DLB, and with greater hippo-
campal and cortical degeneration associated with add-
itional tau deposition observed in mixed DLB with AD,
while AD has the β-amyloid and tau deposition without
the widespread LRP. This also highlights the necessity to
assess more than one pathological feature in diagnosing
these complex syndromes.
Genetics of DLB
By analysing the incidence of familial and sporadic DLB
cases in autopsy-confirmed series, a family history of de-
mentia is more common in DLB compared with controls
[68] and can run in families in an autosomal dominant
inheritance pattern [69]. These studies indicate a genetic
contribution to this disorder. Variants in all 3 members
of the synuclein gene family, α-, β-, and γ-synuclein
affect the risk of developing DLB [70].
γ-Synuclein, aberrantly expressed in many different ma-
lignant tumours, is primarily found in the peripheral ner-
vous system and also detected in brain. β-Synuclein, the
non-amyloidogenic homolog of α-synuclein, is associated
with DLB and not PD. V70M and P123H mutations in the
β-synuclein gene have been shown to predispose to DLB
[71]. In contrast, genetic mutations in the α-synuclein
gene are most commonly associated with PD, with or
without dementia. However, an E46K mutation in the α-
synuclein gene has been found in one Spanish family with
DLB [72] and triplication of the α-synuclein gene occurs
in a Swedish American family with early-onset parkinson-
ism and dementia [73], consistent with current DLB diag-
nostic criteria. However, mutations in the α-synuclein
gene are very rare in familial patients with either PD or
DLB [74,75]. Common genetic factors for the susceptibil-
ity of these LRP disorders have been identified in the glu-
cocerebrosidase (GBA) gene [76]. A significantly higher
heterozygote frequency for two common GBA gene muta-
tions (N370S and L444P) occurs in patients with PD
(2.9%; P <.001) or DLB (3.5%; P = .045) compared with
control subjects (0.4%) [77].
A novel locus for DLB has been identified in Belgian
families [78]. A genome-wide scan and subsequent fine
Figure 1 Lewy-related pathologies (LRP) and Aβ deposition in DLB. (A-C) Histofluorecence identification of α-synuclein-positive (A, green)
Lewy bodies using thioflavin S (B, blue) for filament localization (C, merge) showing difficulty with immunostaining the mature core filaments of
midbrain Lewy bodies. (D) Eosinophilic Lewy body in a pigmented midbrain dopaminergic neuron, (E) mature α-synuclein-positive Lewy body in
the neocortex identified using peroxidase immunohistochemistry, (F) immature α-synuclein-positive Lewy body and related star-shaped α-
synuclein-positive astrocytes in the neocortex identified using peroxidase immunohistochemistry. (G) α-synuclein-positive Lewy neurites in the
hippocampal CA2 region identified using peroxidase immunohistochemistry, and (H) Aβ-positive cortical plaques identified using peroxidase
immunohistochemistry. The scale in F and G is equal to that in E.
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2q35-q36 adjacent to the previously reported PARK11
locus. Screening five candidate genes has not identified
the disease-causing mutation [78]. Further analysis of
AD and PD causative genes in patients with DLB has
been performed showing copy number variants in APP,
SNCA and PARK2 genes [76]. However, as the clinical
diagnosis of DLB remains difficult, whether current
genes associated with either AD or PD pathology influ-
ence all aspects of DLB or more particularly some over-
lapping pathology, remains to be determined. Due to poor
sensitivity of the clinical diagnosis of DLB, identification
of genes causing DLB requires autopsy-confirmation, ren-
dering such studies difficult. Genetic analysis on further
families with multiple autopsies is currently the only way
for breakthroughs in the genetics of DLB.
Conclusions
There is a need for better clinical differentiation of
people who have a distinct pathological process from PD
or AD – that is LRP with β-amyloid deposition but not
overt AD tau pathology. There is also a need to deter-
mine the clinical consequences of LRP deposition alone
without overt parkinsonism or dementia, and the risk
factors for this prodrome. Better definitions and more
sensitive diagnostic procedures are vital for accurate
estimation of prevalence and incidence of DLB across
different populations. Finally, identifying causative genes
in a better defined population of DLB cases is likely to
provide a promising way forward to shed light on any
potential different pathogenic mechanism/s for DLB,
and assist with increasing the accuracy of clinical diag-
nosis for this overlapping dementia syndrome.
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